RevoLix120瓦二微米激光前列腺汽化剜除术治疗高危良性前列腺增生

目的 探讨RevoLix 120 W 2μm激光前列腺汽化剜除术治疗高危良性前列腺增生(BPH)的安全性和有效性.方法 2010年1-12月,采用经尿道RevoLix 120 W 2μm激光前列腺汽化剜除术治疗高危BPH患者62例.观察手术时间、血红蛋白和血清钠变化、留置导尿管时间、手术并发症、国际前列腺症状评分(ⅡSS)、生活质量(QOL)评分、残余尿(PVR)、最大尿流率(Qmax)等指标.结果 手术均顺利完成.手术时间(52.6±28.2) min,无输血病例,术后均无心、脑、肝、肾等系统性疾病加重.术后留置导尿管时间3～6d.手术前后血红蛋白分别为(132±26) g/L和(128±21)g/L,血清钠分别为(142.4±4.9) mmol/L和(141.2±3.8) mmol/L,差异无统计学意义(P＞0.05).62例患者术后随访(7.2±3.5)个月,术后Qmax由术前的(7.6±4.2) ml/s增至(21.8±5.9) ml/s,PVR由术前的( 124.4±206.2) ml降至(21.5±26.5) ml,IPSS及QOL评分分别由术前的(20.4±6.8)、(4.5±0.9)分降至(6.2±2.2)、(2.0±0.3)分,差异有统计学意义(P＜0.01).结论 RevoLix 120W 2μm激光前列腺汽化剜除术治疗高危BPH安全有效,但应掌握手术技巧和加强围手术期处理.     

抗人类免疫缺陷病毒蓝藻蛋白-N研究进展

蓝藻抗病毒蛋白 N (cyanovirin N ,CV N )是一种从椭孢念珠藻 (Nostocelliposporum )中分离出的抗病毒活性蛋白 ,能够有效地抑制多个亚型的人类免疫缺陷病毒Ⅰ (HIV Ⅰ ) ,Ⅱ (HIV Ⅱ )以及猴免疫缺陷病毒 (SIV )。CV N的上述特性使它可能成为艾滋病 (AIDS)的潜在高效治疗药物。大量研究证明 ,CV N与包膜糖蛋白 12 0 (GP12 0 )具有高度亲和性并能够阻断由包膜蛋白介导的细胞融合过程从而阻止病毒的扩散。CV N的出现标志着天然多肽抗艾滋病药物时代的到来     

Central action of prosaptide TX14(A) against gp120‐induced allodynia in rats

We investigated the effect of the prosaposin‐derived peptide prosaptide TX14(A) on tactile allodynia in rats following intraplantar injection of the HIV envelope glycoprotein gp120. Systemic administration of TX14(A) dose‐dependently prevented onset of tactile allodynia following intraplantar injection of gp120 and also transiently alleviated established allodynia in the same model. TX14(A) did not prevent tactile allodynia when injected directly into the foot pad whereas intrathecal administration of TX14(A) both prevented and alleviated gp120‐induced tactile allodynia. Nerve and spinal cord levels of TNFα protein were unchanged in intraplantar gp120 injected rats that displayed allodynia. These results indicate that TX14(A) has anti‐allodynic properties in a rat model of gp120‐induced tactile allodynia and that the mechanism of action of TX14(A) may include modulation of spinal nociceptive processing.     

P120-catenin和E-cadherin的协同表达与肺癌的恶性程度相关

目的方法结果结论探讨p120-catenin(p120ctn)和E-cadherin(E-cad)在非小细胞肺癌中的表达是否具有相关性。方法免疫组织化学S-P法、RT-PCR及WesternBlot等检测肺癌组织中p120ctn和E-cad的表达情况。结果p120ctn和E-cad在肺癌组织中的表达明显低于正常肺组织,并且p120ctn的异常表达与E-cad的异常表达呈正相关。肺癌组织中p120ctn和E-cad的异常表达与肺癌的高分期,低分化和淋巴结转移明显相关。与正常支气管上皮细胞HBE相比,同源的BE1和LH7细胞中都显示出p120ctn、E-cad的表达下降。但在转移能力较高的BE1细胞系中这种异常表达的现象尤为明显。结论肺癌中p120ctn和E-cad的低表达可能与肺癌的恶性度有关。     

Diagnosis and treatment of tuberculous pleural effusion in 2006

Tuberculous (TB) pleural effusion occurs in approximately 5% of patients with Mycobacterium tuberculosis infection. The HIV pandemic has been associated with a doubling of the incidence of extrapulmonary TB, which has resulted in increased recognition of TB pleural effusions even in developed nations. Recent studies have provided insights into the immunopathogenesis of pleural TB, including memory T-cell homing and chemokine activation. The definitive diagnosis of TB pleural effusions depends on the demonstration of acid-fast bacilli in the sputum, pleural fluid, or pleural biopsy specimens. The diagnosis can be established in a majority of patients from the clinical features, pleural fluid examination, including cytology, biochemistry, and bacteriology, and pleural biopsy. Measurement of adenosine deaminase and interferon-gamma in the pleural fluid and polymerase chain reaction for M tuberculosis has gained wide acceptance in the diagnosis of TB pleural effusions. Although promising, these tests require further evaluation before their routine use can be recommended. The treatment of TB pleural effusions in patients with HIV/AIDS is essentially similar to that in HIV-negative patients. At present, evidence regarding the use of corticosteroids in the treatment of TB pleural effusion is not clear-cut.